BioPharmSignal logoBioPharmSignal

Biotech News

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

Altimmune (ALT)AltimmuneEarnings

Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that it will report its third quarter 2026 financial results on Thursday, November 12, 2026.

Related news

ALTAltimmune2026-08-05 12:00 EST

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

ALTAltimmune2026-08-12 11:30 EST

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

MNKDMannKind2026-10-29 20:01 EST

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

MLYSMineralys Therapeutics2026-10-28 20:05 EST

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

ALGSAligos Therapeutics2026-11-06 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

View all latest news

Altimmune

Metabolic and Liver Disease Company Altimmune develops pemvidutide for serious metabolic and liver diseases. Balanced Dual Agonist Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism. MASH Program The global PERFORMA program is...

Recent company news

ALTAltimmune2026-11-05 13:00 EST

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

ALTAltimmune2026-09-23 12:00 EST

Altimmune to Participate in Stifel Cardiometabolic Forum

ALTAltimmune2026-09-03 12:00 EST

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

ALTAltimmune2026-08-12 11:30 EST

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

ALTAltimmune2026-08-05 12:00 EST

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Stock data

Close
1.97 USD
Market cap
563.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States